AR882
Phase 2- Indications
- Gout, Tophaceous gout
Company intelligence / Profile preview
Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.
Guangzhou, Guangdong Sheng, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has a Phase 3 clinical trial for Pozdeutinurad (AR882), a URAT1 inhibitor for the treatment of primary gout. A Phase 2/3 study comparing AR882 capsules to Febuxostat tablets in patients with primary gout and hyperuricemia was reported as "Active, not recruiting" as of September 20, 2024[9].
- Therapeutic areas
- Metabolic DisordersRheumatology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Joint venture between Yipinhong Pharmaceutical Co., Ltd. (also referred to as Guangzhou Yipinhong Pharmaceutical Co., Ltd.) and Arthrosi Therapeutics, Inc.[1][2]
Beyond the preview
Go deeper on Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd..